Home     Site Map     Legal   

  Latest News

January 2020 MBC Pharma, Inc. initiates a clinical trial of GEM-IB in combination with docetaxel in dogs with spontaneous osteosarcoma.
July 15-17, 2019 MBC Pharma Inc. presents Phase I MBC-11 clinical results with PK and 2nd generation lead compound GEM-IB in vivo efficacy at the Bisphosphonates 2019: celebrating 50 years meeting in Sheffield, UK (poster presentation)
March 2019 MBC Pharma Inc. publishes results of MBC-11 Phase I clinical trial demonstrating first-in-class human proof of concept in patients with metastatic bone disease.
September 20, 2017 MBC Pharma Inc. Awarded a SBIR Phase II Grant to Further Develop a Novel
Bone-Targeted Combination Treatment for Osteosarcoma (read more)
August 16, 2017 MBC Pharma, Inc. awarded an SBIR Phase I grant to investigate novel compounds against osteomyelitis (read more)
October 27, 2014 MBC Pharma and Osteros Biomedica announce initiation of Phase 1 clinical trial of MBC-11 in patients with cancer induced bone disease (read more)
September 19, 2012 MBC Pharma and Maxwell Biotech Group partner to clinically develop a new anti-tumor drug candidate MBC-11 targeting metastatic bone disease (read more)
May 25, 2012 MBC Pharma, Inc. wins a legal battle against Cedarburg Hauser Pharmaceuticals (read more)

  Key Publications
  1. Farrell, K.B., Zinnen, S.P., Thamm, D.H., Karpeisky, A. (2021) Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel. Bioconjug. Chem., 32, 12, 2530-2539 PubMed PMID: 34779607; PubMed Central PMCID: PMC9773925.
  2. Zinnen, S.P., Karpeisky, A., Von Hoff, D.D., Plekhova, L., Alexandrov, A. (2019) First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist, 24 3, 303-e102 PubMed PMID: 30413669; PubMed Central PMCID: PMC6519757.
  3. Farrell, K.B., Karpeisky, A., Thamm, D.H., Zinnen, S. (2018) Bisphosphonate conjugation for bone specific drug targeting Bone Rep., 9 , 47-60 PubMed PMID: 29992180; PubMed Central PMCID: PMC6037665.
  4. Reinholz, M. M., Zinnen, S. P., Dueck, A. C., Dingli, D., Reinholz, G. G., Jonart, L. A., Kitzmann, K. A., Bruzek, A. K., Negron, V., Abdalla, A. K., Arendt, B. K., Croatt, A. J., Sanchez-Perez, L., Sebesta, D. P., Lonnberg, H., Yoneda, T., Nath, K. A., Jelinek, D. F., Russell, S. J., Ingle, J. N., Spelsberg, T. C., Dixon, H. B., Karpeisky, A., Lingle, W. L., (2010),A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites Bone , 47 73, 12-22
  5. Mikko Ora, Tuomas Lonnberg, Diana Florea-Wang, Shawn Zinnen,Alexander Karpeisky, and Harri Lonnberg (2008)  Bisphosphonate Derivatives of Nucleoside Antimetabolites:
    Hydrolytic Stability and Hydroxyapatite Adsorption of 5′-β,γ-Methylene and 5′-β,γ-(1-Hydroxyethylidene) Triphosphates of 5-Fluorouridine and ara-Cytidine. JOC, 73, 4123-30
  6. Zinnen, S.,Sebesta, D., Karpeisky, A., Guzaev, A., (2006) Novel vitamin B6 derivative of alendronate rapidly absorbed following oral administration. Bone 38, S64
  7. Reinholz, M., Reinholz, G., Arendt, B., Jelinek, D., Kitzmann, K., Dingli, D., Russel, S., W., L., and Karpeisky, A. (2005). Novel bisphosphonate conjugates inhibit multiple myeloma cell proliferation in vitro and increase bone mineral density and prolong survival in a mouse multiple myeloma model. Cancer Treatment Reviews 31, abstract # 119.
  8. Reinholz, M., Reinholz, G., Jonart, L., Yoneda, T., Spelsberg, T., Lingle, W., and Karpeisky, M. (2004). Novel bisphosphonate conjugates decrease metastatic bone tumor burden in the 4T1/luc mouse model of breast cancer. Journal of Bone and Mineral Research 19, S66.
  9. Reinholz, M., Jonart, L., Reinholz, G., Spelsberg, T., Lingle, W., Yoneda, T., and Karpeisky, M. (2004). The effects of novel bisphosphonate conjugates on primary breast tumor burden and soft organ metastases in the 4T1/luciferase mouse model of breast cancer. Breast Cancer Research and Treatment 88, S133.
  10. Reinholz, G.G., Getz, B., Sanders, E.S., Karpeisky, M.Y., Padyukova, N., Mikhailov, S.N., Ingle, J.N., and Spelsberg, T.C. (2002). Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Research and Treatment 71, 257-268

MBC Pharma, Inc.   12635 E. Montview Blvd., Suite 100  Aurora, CO 80045
Phone: 720-859-4041  Fax: 720-770-3255
Email: information@mbcpharma.com